Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral PresentationGlobeNewsWire • 05/10/24
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple MyelomaGlobeNewsWire • 04/29/24
Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)GlobeNewsWire • 04/15/24
Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical TrialGlobeNewsWire • 03/20/24
Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness InitiativeGlobeNewsWire • 03/05/24
Immix Biopharma Announces Closing of $15 Million Public Offering of Common StockGlobeNewsWire • 02/08/24
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL AmyloidosisGlobeNewsWire • 02/07/24
Immix Biopharma Announces Pricing of $15 Million Public Offering of Common StockGlobeNewsWire • 02/06/24
Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T ProductsGlobeNewsWire • 01/24/24
Immix Biopharma Announces Dr. Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory BoardGlobeNewsWire • 12/18/23
Immix Biopharma Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2023GlobeNewsWire • 12/11/23
Immix Biopharma to Present at the 2023 JMP Securities Hematology and Oncology SummitGlobeNewsWire • 11/30/23
What Makes Immix Biopharma, Inc. (IMMX) a Good Fit for 'Trend Investing'Zacks Investment Research • 11/28/23
Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL AmyloidosisGlobeNewsWire • 11/22/23
Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient DosingGlobeNewsWire • 11/21/23
Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis PatientsGlobeNewsWire • 11/06/23
Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 63 Relapsed/Refractory Multiple Myeloma PatientsGlobeNewsWire • 11/06/23
Here's Why Immix Biopharma, Inc. (IMMX) Is a Great 'Buy the Bottom' Stock NowZacks Investment Research • 10/31/23
Immix Biopharma Subsidiary Nexcella Announces Dr. Michaela Liedtke, Stanford Medicine Cancer Center Hematology Program Lead and Co-Director Stanford Amyloid Center, Joins Scientific Advisory BoardGlobeNewsWire • 10/26/23
Immix Biopharma Completes 3rd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing SiteGlobeNewsWire • 10/16/23